Five prognostic biomarkers—ITGB2, VIP, PTK2, FHL2, and BAG3—were identified and integrated into a novel risk model to stratify patients with AML into high- and low-risk groups. The gene discussed is FHL2; the disease is acute myeloid leukemia.